According to Puurunen et al. [26], in a group of 1946 participants with stable CAD from the ARTEMIS trial, leptin had predictive value for the primary composite endpoint (MACE defined as CHF hospitalization or cardiac death) and the secondary endpoint (ACS or stroke) over a follow-up period of 2 years. This evidence concerns the gene LEP and coronary artery disorder.